Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period
|
|
- Matthew Lloyd
- 5 years ago
- Views:
Transcription
1 Acta Obstetricia et Gynecologica. 2008; 87: ORIGINAL ARTICLE Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period CHARLOTTE GERD HANNIBAL 1, RIKKE CORTES 2, GERDA ENGHOLM 2 & SUSANNE KRÜGER KJAER 1,3 1 Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark, 2 Department of Cancer Prevention and Documentation, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark, 3 Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark Abstract Objective. To explore the variation in ovarian cancer survival in Denmark in the period in relation to time since diagnosis, age at diagnosis, period of diagnosis, stage and histology. Design. Register-based cohort study. Setting. Denmark in the period Population. Using the nationwide Danish Cancer Registry, we included a total of 13,035 women diagnosed with invasive ovarian cancer in Denmark in the period Methods. Excess mortality risk analyses of fiveyear relative survival of ovarian cancer patients diagnosed in the period with follow-up through 2006 were made based on data from the NORDCAN database. Main outcome measures. Five-year relative survival, excess mortality rate (ER) and relative excess mortality risk (RER) after an ovarian cancer diagnosis. Results. The relative survival of Danish ovarian cancer patients slightly increased in the period The ERs were highest in the first year following diagnosis, in particular in the first three months, and among older patients, even for localized and regional tumors. The pattern remained the same when stratified by histological subgroup. Older age at diagnosis, earlier period of diagnosis, more advanced stage at diagnosis and being diagnosed with undifferentiated carcinoma predicted poorer survival among Danish ovarian cancer patients diagnosed in the period Conclusions. The survival of Danish ovarian cancer patients has slightly increased from 1978 through Despite this, the mortality rate of ovarian cancer in Denmark is still higher than in the other Nordic countries. Explanations for these differences are still to be identified. Key words: Ovarian cancer, cancer registry, population based, excess mortality risk analysis Abbreviations: CI: confidence interval, DCO: death certificate only, ER: excess rate, FIGO: International Federation of Gynecology and Obstetrics, GLM: General Linear Models, RER: relative excess risk Introduction Worldwide, ovarian cancer is the sixth most frequent cancer in women, with 200,000 new cases diagnosed every year, and the most lethal of all being gynecological cancers (1). Given that ovarian cancer in 75% of cases is diagnosed in advanced stage, the disease has a fairly poor prognosis with an overall five-year survival of around 40%, ranging from 10% for patients with tumors with distant metastases to 80% for patients with localized tumors (24). There is marked geographical variation in agestandardized incidence and mortality rates of ovarian cancer, with the highest rates observed in Northern and Western Europe, notably Scandinavia, and in North America (5). Even within the Nordic countries, there are striking differences in the mortality rates of ovarian cancer despite similarities in the incidence rates and management of health care systems (57). In Denmark, the age-standardized incidence rate of ovarian cancer has decreased during the last 25 years, Correspondence: Susanne Krüger Kjaer, Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark. susanne@cancer.dk (Received 4 July 2008; accepted 16 September 2008) ISSN print/issn online # 2008 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS) DOI: /
2 1354 C.G. Hannibal et al. whereas a more substantial decrease has been observed in the mortality rate (8). Similar patterns have been seen in the other Nordic countries; nevertheless, Denmark has had the highest mortality rate in the world during the entire period (5,8). The decreasing mortality rate may be due to earlier diagnosis and improved treatment. There is no active screening for ovarian cancer yet, but increasing access to more specific diagnostic methods, such as ultrasound and tumor markers (e.g. CA125), may explain the trend towards diagnosis at earlier stages (8). In this paper, we explored the variation in ovarian cancer survival in Denmark during the period in relation to time since diagnosis, age at diagnosis, period of diagnosis as well as stage and histological subgroup. Material and methods Material From the Danish Cancer Registry we identified a total of 14,660 women diagnosed with ovarian cancer (ICD-10: C56, C57.0-4) in the period The ICD-10 codes are based on a conversion from the registration of diagnosis according to ICD-O-1 in the Danish Cancer Registry to the NORDCAN database. NORDCAN contains cancer incidence and mortality from the five Nordic countries. Different classification systems have been used over time in the Nordic countries, and in NORD- CAN conversions to groups of diagnoses based on ICD-10 have been formed for better comparability between counties over time (6). Patients with a previous cancer diagnosis (n 1,062), disregarding non-melanoma skin cancer, a simultaneous cancer at the time of the ovarian cancer diagnosis (n 318) and patients with ovarian cancer only, but detected at autopsy or identified by death certificate only (DCO) (n 245), were excluded from analysis. We included a total of 13,035 women with ovarian cancer recorded as the first invasive cancer among women aged 1589 years in the period Follow-up for death or emigration was made through 2006, but only follow-up in the first five years after diagnosis was used and for those diagnosed in 2002 only to the end of 2006, i.e. follow-up between four and five years. Variables available to the analysis were: month and year of birth, diagnosis and death or emigration, time since diagnosis, ICD-10 code, basis of diagnosis, vital status at end of follow-up, topography, stage and histology. The extent of the disease at time of diagnosis was reported as localized tumor, tumor with regional spread, tumor with distant metastases or alternatively as stage according to the International Federation of Gynecology and Obstetrics (FIGO) classification. In this paper, we divided cases into four groups: localized tumors (stage I), tumors with regional spread (stages II and III), tumors with distant metastases (stage IV) and tumors with unknown extent of disease. Data on all-cause mortality for the Danish population originally stems from the databank of Statistics Denmark, but was here retrieved from the Human Mortality Database ( To secure more stable population mortality rates, five-years running means over years were used of the one-year age- and period-specific morality rates. Statistical analyses Relative survival is defined as the ratio between the observed survival within the patient group and the expected survival if the group has the mortality of the Danish population. Five-year relative survival was calculated using the SAS-macros described by Dickman et al. (9). Relative survival was age-standardized using a slightly modified version of the age distribution standard version used in EUROCARE (10). The modifications were more detailed age-groups above age 60 years and a weight of zero for ages 90 years and above at diagnosis. Modeling of the five-year relative survival was made using its counterpart in mortality, the excess mortality rate (ER), the difference between the observed and the expected all-cause mortality rates and analyzing it by Poisson regression models, here called excess mortality risk modeling. We used exact survival time, collapsed data and General Linear Models (GLM) with a Poisson error structure (9). Excess mortality risk models assume constant excess rates in intervals of follow-up. An ER can be expressed as the excess number of deaths per 100 person-years, excess to the expected number of deaths derived from population mortality rates. Modeling of the ER was explored using the explanatory factors: time since diagnosis, age at diagnosis, period of diagnosis, stage at diagnosis and histological subgroup. The first year is often the most heterogeneous year in survival analysis (9). Therefore, we subdivided the first year of follow-up using the intervals 02 months, 35 months and 612 months. The remaining follow-up time was categorized as follows: 12, 23, 34 and 45 years after diagnosis. Age groups were 1549, 5059, 6069, 7079 and 8089 years, period of diagnosis were , , , and , and stages were localized, regional, distant metastases and unknown. The histological diagnosis was categorized as undifferentiated carcinomas, adenocarcinomas, serous tumors,
3 Survival of Danish ovarian cancer patients 1355 mucinous tumors, endometrioid tumors, non-epithelial tumors and clear cell neoplasms. Plots of the agespecific observed ER curves by follow-up intervals showed the overall pattern, the pattern by stage and by histological subgroup. The deviance with degrees of freedom for a model evaluated in a Chi-square distribution was used as goodness-of-fit of the model. Modeling of the ER in the first five years following diagnosis revealed that it was only possible to fit relatively simple models without interactions by restricting analyses to the follow-up interval 6 months to 5 years and ages 1579 years at diagnosis. In addition, it was only possible to fit a simple model with histological subgroups by including only some specific subgroups. Statistical modeling was carried out using the SAS version 9.1. Results Table I shows no major differences in the distribution of age and stage at diagnosis over time; although the percentage of distant metastasis decreased together with a slight increase in the other groups. However, the percentage of some histological subgroups decreased from 1978 through 2002 (undifferentiated carcinoma, adenocarcinoma), whereas others increased (serous, endometrioid, clear cell) or remained the same (mucinous, non-epithelial). In general, most women were diagnosed between 60 and 69 years, had tumors with regional spread and had serous tumors. The percentage of excluded patients due to incidental findings at autopsy or DCO notifications decreased over time, from around 3% at the start of the study period to B1% in the period The age-standardized incidence rate (as a first cancer) decreased slightly over time from 18.3 per 100,000 in to 16.9 per 100,000 in The age-standardized mortality rate decreased somewhat more over time and was highest in the period with 15.4 per 100,000 and lowest at the end of the study period (13.1 per 100,000). The mortality-incidence ratio is a coarse indicator of completeness and case fatality, and generally decreased over time from 80.1% in to 74.2% in A short length of survival (02 months after diagnosis) was strongly related to age, with an increasing percentage of older women having shorter survival (Table II). Similarly, stage at diagnosis influenced the survival time. Whereas only 2% of Table I. Characteristics of the study population of ovarian cancer patients without a previous or simultaneous other cancer, aged 1589 years at diagnosis in the period in Denmark, and general measures for all ovarian cancer patients in the period. Period of diagnosis (n2,601) (n2,617) (n2,553) (n2,577) (n2,687) Age at diagnosis (years) (%) Stage at diagnosis (%) Localized Regional Distant metastases Unknown Histological subgroup (%) Undifferentiated carcinoma Adenocarcinoma Serous Mucinous Endometrioid Non-epithelial Clear cell Incidental finding at autopsy, and DCO$ (%) Age-standardized incidence rate per 100,000%, Age-standardized mortality rate per 100,000%, Mortalityincidence ratio (%) $Death certificate only (DCO). %All ages and age-standardized to the European standard population. Only first cancers
4 1356 C.G. Hannibal et al. women with localized disease died within the first three months, more than one-third of women with distant metastases died during the first three months following diagnosis. Finally, a slightly higher percentage of women diagnosed in the period died within the first three months compared to women diagnosed in more recent periods. Figure 1 shows the age-standardized five-year relative cohort survival divided by stage and period in in Denmark. In general, the relative survival of ovarian cancer patients has slightly increased in Denmark since For the entire period, the relative survival was lowest for patients diagnosed with tumors with distant metastases followed by patients with tumors with regional spread and unknown stage, whereas patients with localized tumors by far had the highest five-year relative survival. Figure 2 shows the overall pattern of age-specific observed ERs by follow-up interval for the ovarian cancer patients diagnosed during the years For all age groups older than 49 years, the level of the ER was decreasing with longer time since diagnosis. In the shortest follow-up interval, 02 months after diagnosis, a large increase was seen in the ER with age, especially after 60 years. A similar, but less strong, pattern was seen for the two following periods (35 months and 612 months after diagnosis). For longer follow-up intervals, there was practically no association with age. When the age and follow-up specific ERs were stratified by stage, the patterns were fairly similar. For tumors with distant metastases and tumors with unknown stage, the largest increase in the ER was observed in the first follow-up interval, 02 months after diagnosis, especially among older women (Figure 3AD). In addition, a large increase in the ER in the first follow-up interval, 02 months after diagnosis, was observed among women 6070 years or older who had localized tumors and tumors with regional spread. Looking at the different histological subgroups, the largest increase in the ER was still seen in the first follow-up interval, 02 months after diagnosis, although the level of the rate by age differed between subgroups (data not shown). For undifferentiated carcinomas, adenocarcinomas and non-epithelial tumors, the ER in the first follow-up interval, 02 months after diagnosis, was significantly increased compared with the case for serous, mucinous and endometrioid tumors as well as clear cell neoplasms. Also, for undifferentiated carcinomas and adenocarcinomas, the large increase was seen over the whole age span, whereas for the other histological subgroups the increase was not apparent until after around 60 years. When comparing the age and follow-up specific ERs between different time periods, the patterns were fairly similar; however, the ER was, in general, slightly lower in the more recent periods, which was most evident for the shorter follow-up intervals (data not shown). Table III shows modeling of the ERs and relative excess mortality risks among patients aged 1579 years who had survived the first six months after diagnosis. The ER for the reference group (6069 Table II. Distribution of length of survival for Danish ovarian cancer patients diagnosed in the period by age at diagnosis, period of diagnosis and stage at diagnosis. Length of survival p-value n 02 months (%) 35 months (%) 6 months (%) Age at diagnosis B (years) , , , , , Period of diagnosis B , , , , , Stage at diagnosis B Localized 2, Regional 5, Distant metastases 3, Unknown
5 Survival of Danish ovarian cancer patients 1357 Figure 1. Age-standardized five-year relative survival for Danish ovarian cancer patients over calendar time according to stage. years and period of diagnosis ) decreased with increasing follow-up time, from 37 excess deaths per 100 person-years 6 months to 1 year after diagnosis, to 10 excess deaths per 100 personyears 45 years following diagnosis (Table III). The relative excess mortality risk varied with age, as women aged 1549 years had the lowest risk with a statistically significant 46% lower excess mortality risk compared to women aged 6069 years after adjustment for follow-up time and period of diagnosis. In addition, compared to women diagnosed in the period , women diagnosed in the years had a statistically significant 20% Figure 2. Age-specific observed excess mortality rates by followup interval for Danish ovarian cancer patients diagnosed in the period lower excess mortality risk. After including stage in the model (using regional spread as reference), the ERs and relative risks changed slightly. Compared to women diagnosed with tumors with regional spread, women having tumors with distant metastases had a statistically significant 82% higher excess mortality risk, whereas women with unknown stage and localized tumors had a statistically significant lower excess mortality risk, 39% and 83%, respectively. In a model including histology with serous tumors as reference, we found that women with undifferentiated carcinoma tumors had a statistically significant 38% higher excess mortality risk and women with non-epithelial tumors had a borderline statistically significant 15% lower excess mortality risk, whereas women with mucinous tumors had the same risk, after adjustment for follow-up time, age, period and stage at diagnosis (data not shown). Discussion We found a substantial variation in ovarian cancer survival with a higher ER within the first year after diagnosis and among older patients, most evident in the first three months and after 60 years, compared to longer follow-up times and younger patients. The pattern remained fairly much the same when stratified by stage or by histological subgroup. Older age at diagnosis, more advanced stage and undifferentiated carcinomas were the most important factors in the analysis, and predicted poorer survival among Danish ovarian cancer patients diagnosed from 1978 through We found that the ER was highest during the first three months after diagnosis and among older patients. The pattern was evident even for localized and regional tumors. This might be explained by existing co-morbidity or because older women are less likely to tolerate treatment or do not want to be treated. Few population-based studies have reported survival rates of different histological subgroups over time. We found a better prognosis among women diagnosed with non-epithelial tumors compared to women diagnosed with serous tumors, but a much poorer prognosis among women diagnosed with undifferentiated carcinomas, whereas mucinous tumors had a similar risk to serous tumors. This is partly in line with a Norwegian study by Bjorge et al. (11) who also found a poorer prognosis for patients diagnosed with undifferentiated tumors compared to serous tumors, but a better prognosis among women diagnosed with mucinous tumors. The age-standardized five-year relative survival increased slightly for all stages of ovarian cancer
6 1358 C.G. Hannibal et al. Figure 3. (AD) Age-specific observed excess mortality rates by follow-up interval for Danish ovarian cancer patients diagnosed in the period by stage at diagnosis. during the study period from 1978 through Women diagnosed with localized tumors had a much more favorable prognosis compared to women diagnosed with more advanced stages during the entire period. As shown in a recent EUROCARE-4 study, the five-year age-adjusted relative survival for ovarian cancer patients increased in Europe from 1990 through 1999; however, Denmark has had one of the poorest survivals compared to the other European countries in that period (12). Cancer survival is a complex indicator of a country s performance in managing cancer. Improvements in cancer survival may reflect earlier diagnosis or later death. Better survival might also be derived from inclusion of a number of patients identified at screening, where the tumor would not otherwise have progressed to give clinical signs. So far, no screening method for ovarian cancer exists, but increasing access to more specific diagnostic methods, such as ultrasound and the tumor marker CA125, may explain the trend towards earlier stages at diagnosis (8). In two ongoing studies examining screening for ovarian cancer, results have suggested that the tumor marker CA125 can lead to discover-
7 Survival of Danish ovarian cancer patients 1359 Table III. Models for excess mortality in the first five years among Danish ovarian cancer patients diagnosed in the period , aged 1579 years, among patients who survived the first half year following diagnosis. ER$, 95% CI p ER%, 95% CI p Follow-up time (years) (3340) 39 (3542) (3237) 40 (3744) (2226) 31 (2834) (1215) 19 (1722) (811) 14 (1217) RER RER Age at diagnosis (years) B0.01 B ( ) 0.62 ( ) ( ) 0.88 ( ) (ref.) 1 (ref.) ( ) 1.26 ( ) Period of diagnosis B0.01 B ( ) 1.20 ( ) (ref.) 1 (ref.) ( ) 1.01 ( ) ( ) 0.89 ( ) ( ) 0.72 ( ) Stage at diagnosis B0.01 Localized 0.17 ( ) Regional 1 (ref.) Distant metastases 1.82 ( ) Unknown 0.61 ( ) ER, excess rate; RER, relative excess risk, relative to the reference category. $Excess deaths per 100 person-years for patients aged 6069 years at diagnosis in the years %Excess deaths per 100 person-years for patients aged 6069 years with regional stage in the years Adjusted for all other variables in the table except for stage at diagnosis. Adjusted for all other variables in the table. ing of more cases of ovarian cancer (13). Whether or not this will influence the mortality or just lead to the detection of more cases is a question. As shown in the paper by Kjaerbye-Thygesen et al. (8) as well as in the present paper, it is reassuring that the mortality rate of ovarian cancer has decreased in Denmark over the last 25 years; yet Denmark still has the highest ovarian cancer mortality rate observed worldwide (5). Kjaerbye-Thygesen et al. (8) showed that compared to the other Nordic countries, Denmark has had the highest ovarian cancer mortality rate during the entire period This is surprising considering the similarities in ovarian cancer incidence (8) and health care systems in the Nordic countries in the same period (6). In general, it appears that Danish cancer patients overall had the same survival as patients in the other Nordic countries in the 1950 and 1960s, but did not experience the same level of improvement in prognosis during the later decades (14). In the present study, we found that 19.3% of women had localized tumors at time of diagnosis. This is a much smaller fraction compared to some of the other Nordic countries around the same time, since they found fractions of 2430% (15). The fact that more patients in Denmark seem to be diagnosed with ovarian cancer at more advanced stages might explain the higher ovarian cancer mortality observed in Denmark compared to the other Nordic countries. This is not only the case for ovarian cancer, but it appears that Danish cancer patients in general are diagnosed in more advanced stages of disease than patients in the other Nordic countries, taking into consideration that the classification of localized tumors is quite similar in the countries (14). Thus, a different distribution between countries of the diagnoses in later stages might explain the cancer survival differences within the Nordic countries, but to examine if the differences in survival are actually due to different diagnostic practices is difficult using cancer registry data only. In the present study, we included data from the Danish Cancer Registry and the NORDCAN database, which is high quality data as it is nationwide and population based. In addition, we used the unique nature of the Danish personal identification number, implying a virtually complete follow-up. In our study, we assessed excess mortality risk and relative survival, whereas most other studies have
8 1360 C.G. Hannibal et al. assessed only relative survival. The advantage of using excess mortality risk is that the estimates represent the specific ovarian cancer mortality after subtracting the general background mortality. In conclusion, the mortality of Danish ovarian cancer patients has slightly decreased in the period Older age, more advanced stage and having undifferentiated carcinomas at time of diagnosis seem to be important factors in explaining the poorer survival among Danish ovarian cancer patients during the last 25 years. It is striking that Denmark still has the highest ovarian cancer mortality rate in the world and thus a much higher ovarian cancer mortality rate than in the other Nordic countries. Explanations for these differences are still to be identified. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. References 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, CA Cancer J Clin. 2005;55: Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period Eur J Cancer. 1998;34: Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003;101: Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann HA, Crommelin M, van Wijck DJ, et al. Improved prognosis of ovarian cancer in The Netherlands during the period : a registry-based study. Gynecol Oncol. 1991;42: Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon: IARC Press; Engholm G, Ferlay J, Christensen N, Bray F, Klint Å, Ólafsdóttir E, et al. NORDCAN: cancer incidence, mortality and prevalence in the Nordic countries, Version 3.2. Association of Nordic Cancer Registries. Danish Cancer Society ( Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in Eur J Cancer. 2002;38: Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark Comparison with other Nordic countries. Acta Obstet Gynecol Scand. 2005;84: Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23: Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40: Bjorge T, Engeland A, Hansen S, Trope CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and Int J Cancer. 1998;75: Berrino F, De AR, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in : results of the EUROCARE-4 study. Lancet Oncol. 2007;8: Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol. 2006;49: Engeland A, Haldorsen T, Dickman PW, Hakulinen T, Moller TR, Storm HH, et al. Relative survival of cancer patients a comparison between Denmark and the other Nordic countries. Acta Oncol. 1998;37: Bjorge T, Engeland A, Hansen S, Trope CG. Trends in the incidence of ovarian cancer and borderline tumours in Norway, Int J Cancer. 1997;71:7806.
Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study
EUROCARE-5 on-line database Data and methods Extract from Cancer survival in Europe 1999 2007 by country and age: results of EUROCARE-5 a population-based study De Angelis R, Sant M, Coleman MP, Francisci
More informationDo morphology and stage explain the inferior lung cancer survival in Denmark?
Eur Respir J 1999; 13: 430±435 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Do morphology and stage explain the inferior lung cancer
More informationANCR. PC-NORDCAN version 2.4
PC-NORDCAN version 2.4 A PC based program for presentation of regional and national cancer incidence and mortality in the Nordic countries. Present facilities Sponsored by Powered by ANCR 1 Reference Gerda
More informationMeasuring and predicting cancer incidence, prevalence and survival in Finland
Measuring and predicting cancer incidence, prevalence and survival in Finland Timo Hakulinen and Karri Seppä Finnish Cancer Registry- the Institute for Statistical and Epidemiological Cancer Research ABSTRACT
More informationDownloaded from:
Coleman, MP; Quaresma, M; Butler, J; Rachet, B (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK Reply. Lancet, 377 (9772). pp. 1149-1150. ISSN 0140-6736 Downloaded from:
More informationInvasive cancer of the cervix is considered a preventable disease because it has a long pre
Focused Issue of This Month Epidemiology of Cervical Cancer Kyu Wan Lee, MDJae Yun Song, MD Department of Obstetrics and Gynecology, Korea University College of Medicine Email : pumplee@kumc.or.kryuni105@yahoo.co.kr
More informationThe validity of the mortality to incidence ratio as a proxy for site-specific cancer survival
European Journal of Public Health, Vol. 21, No. 5, 573 577 ß The Author 2010. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved. doi:10.1093/eurpub/ckq120
More informationHormone therapy and ovarian borderline tumors: a national cohort study
Cancer Causes Control (2012) 23:113 120 DOI 10.1007/s10552-011-9860-2 ORIGINAL PAPER Hormone therapy and ovarian borderline tumors: a national cohort study Lina Steinrud Mørch Ellen Løkkegaard Anne Helms
More informationDownloaded from:
Gauci, D; Allemani, C; Woods, L (2016) Population-level cure of colorectal cancer in Malta: An analysis of patients diagnosed between 1995 and 2004. Cancer epidemiology, 42. pp. 32-38. ISSN 1877-7821 DOI:
More informationTetsuro Yahata, Chiaki Banzai, Kenichi Tanaka and Niigata Gynecological Cancer Registry
645..650 doi:10.1111/j.1447-0756.2011.01755.x J. Obstet. Gynaecol. Res. Vol. 38, No. 4: 645 650, April 2012 Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in
More informationTHE PROCESS OF CANCER REGISTRY DATA QUALITY EVALUATION
THE PROCESS OF CANCER REGISTRY DATA QUALITY EVALUATION Nadya Dimitrova OUTLINE Introduction Comparability Completeness Validity Timeliness CANCER REGISTRATION IN EUROPE Cancer registry (CR) is: an information
More informationONCOLOGY REPORTS 18: , 2007
ONCOLOGY REPORTS 18: 1051-1059, 2007 Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: From the MALOVA Ovarian Cancer Study ESTRID V.S.
More informationFactors Relating to Poor Survival Rates of Aged Cervical Cancer Patients: a Population-based Study with the Relative Survival Model in Osaka, Japan
Factors Relating to Poor Survival of Aged Cervical Cancer Patients in Japan RESEARCH COMMUNICATION Factors Relating to Poor Survival Rates of Aged Cervical Cancer Patients: a Population-based Study with
More informationSurvival in Teenagers and Young. Adults with Cancer in the UK
Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children
More informationLong-term survival of cancer patients in Germany achieved by the beginning of the third millenium
Original article Annals of Oncology 16: 981 986, 2005 doi:10.1093/annonc/mdi186 Published online 22 April 2005 Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium
More informationRelation of Height and Body Mass Index to Renal Cell Carcinoma in Two Million Norwegian Men and Women
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 12 Printed in U.S.A. DOI: 10.1093/aje/kwh345 Relation of Height
More informationSurvival Rates of Childhood Cancer Patients in Osaka, Japan
Jpn J Clin Oncol 2004;34(1)50 54 Epidemiology Note Survival Rates of Childhood Cancer Patients in Osaka, Japan Wakiko Ajiki, Hideaki Tsukuma and Akira Oshima Department of Cancer Control and Statistics,
More informationReport on Cancer Statistics in Alberta. Breast Cancer
Report on Cancer Statistics in Alberta Breast Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the
More informationThe Impact of Comorbidity and Stage on Ovarian Cancer Mortality: A Nationwide Danish Cohort Study
Boston University OpenBU Department of Epidemiology http://open.bu.edu SPH Epidemiology Papers 2008-1-29 The Impact of Comorbidity and Stage on Ovarian Cancer Mortality: A Nationwide Danish Cohort Study
More informationReport on Cancer Statistics in Alberta. Melanoma of the Skin
Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationSpecial issue: NORDCAN Cancer data from the Nordic countries
Special issue: NORDCAN Cancer data from the Nordic countries Editor: Siri Larønningen Writing group: Siri Larønningen, Inger Kristin Larsen, Bjørn Møller, Gerda Engholm 1, Hans H. Storm 1 and Tom Børge
More informationOvarian cancer is the seventh
Survival of Australian women with invasive epithelial ovarian cancer: a populationbased study Satyamurthy Anuradha MB BS, FRCS, PhD Research Officer 1 Penelope M Webb MA, DPhil Head 1 Penny Blomfield MB
More informationMortality from cancer of the lung in Serbia
JBUON 2013; 18(3): 723-727 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Mortality from cancer of the lung in Serbia M. Ilic 1, H. Vlajinac 2,
More informationMethodology for the Survival Estimates
Methodology for the Survival Estimates Inclusion/Exclusion Criteria Cancer cases are classified according to the International Classification of Diseases for Oncology - Third Edition (ICDO-3) Disease sites
More informationRESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry
DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationPrognosis for ovarian cancer in Denmark :
Prognosis for ovarian cancer in Denmark 1980-2005: Studies of use of hospital discharge data to monitor and study prognosis and impact of comorbidity and venous thromboembolism on survival PhD thesis Mette
More informationReport on Cancer Statistics in Alberta. Kidney Cancer
Report on Cancer Statistics in Alberta Kidney Cancer November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the Report
More informationOvarian cancer in Manitoba: trends in incidence and survival,
ORIGINAL ARTICLE Ovarian cancer in Manitoba: trends in incidence and survival, 1992 2011 P. Lambert msc,* K. Galloway msc,* A. Altman md, M.W. Nachtigal phd, and D. Turner phd* # ABSTRACT Background Because
More informationClinical statistics of gynecologic cancers in Japan
J Gynecol Oncol. 2017 Mar;28(2):e32 pissn 2005-0380 eissn 2005-0399 Review Article Clinical statistics of gynecologic cancers in Japan Wataru Yamagami, 1,7 Satoru Nagase, 2,7 Fumiaki Takahashi, 3 Kazuhiko
More informationTitleClinical efficacy of ovarian cancer. Author(s) Koshiyama, Masafumi; Matsumura, Nor. Citation Journal of Cancer (2016), 7(10): 13
TitleClinical efficacy of ovarian cancer Author(s) Koshiyama, Masafumi; Matsumura, Nor Citation Journal of Cancer (2016), 7(10): 13 Issue Date 2016 URL http://hdl.handle.net/2433/225075 Ivyspring International
More informationComparison of Survival Rates between Chinese and Thai Patients with Breast Cancer
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.15.6029 RESEARCH ARTICLE Comparison of Survival Rates between Chinese and Thai Patients with Breast Cancer Yanhua Che 1,4, Jing You 2, Shaojiang Zhou 3, Li Li
More informationPopulation Based Survival of Female Breast Cancer Cases in Riyadh Region, Saudi Arabia
RESEARCH COMMUNICATION Population Based Survival of Female Breast Cancer Cases in Riyadh Region, Saudi Arabia K Ravichandran 1, Nasser Al Hamdan 2, Abdul Rahman Al Dyab 3 Abstract Breast cancer is the
More informationChildhood and adolescent ovarian malignant tumors in Israel A nationwide study
Acta Obstet Gynecol Scand 1999; 78: 813 817 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationD ifferences in colorectal cancer survival between
268 COLORECTAL CANCER Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery L Ciccolallo, R Capocaccia, M P Coleman, F Berrino, J W W Coebergh,
More informationStatin use and risk of endometrial cancer: a nationwide registry-based case control study
AOGS ORIGINAL RESEARCH ARTICLE : a nationwide registry-based case control study CECILIE D. SPERLING 1, FREIJA VERDOODT 1, SØREN FRIIS 2,3,4, CHRISTIAN DEHLENDORFF 2 & SUSANNE K. KJAER 1,5 1 Virus, Lifestyle
More informationTOPIC Presenter Rihab Sidahmed Ibnoaf Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan.
Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan. Ovarian cancer is the seventh most common cancer, and it is the most common cause of mortality from gynecological
More informationCancer in Norway 2011
Cancer in Norway 11 Cancer incidence, mortality, survival and prevalence in Norway Special issue: NORDCAN Cancer data from the Nordic countries Cancer in Norway 11 Editor-in-chief: Inger Kristin Larsen
More informationBleeding symptoms and subsequent risk of gynecological and other cancers
Acta Obstet Gynecol Scand 1998; 77: 564 569 Copyright C Acta Obstet Gynecol Scand 1998 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationRESEARCH. What is already known on this topic. What this study adds
Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation
More informationCancer survival and prevalence in Tasmania
Cancer survival and prevalence in Tasmania 1978-2008 Cancer survival and prevalence in Tasmania 1978-2008 Tasmanian Cancer Registry University of Tasmania Menzies Research Institute Tasmania 17 Liverpool
More informationIncidence and mortality of laryngeal cancer in China, 2011
Original Article Incidence and mortality of laryngeal cancer in China, 2011 Lingbin Du 1, Huizhang Li 1, Chen Zhu 1, Rongshou Zheng 2, Siwei Zhang 2, Wanqing Chen 2 1 Zhejiang Provincial Office for Cancer
More informationNational comparisons of lung cancer survival in England, Norway and Sweden 2001e2004: differences occur early in follow-up
1 Division of Cancer Studies, King s College London, School of Medicine, London, UK 2 Regional Oncological Centre, Uppsala/Örebro Region, Uppsala, Sweden 3 Department of Medical Epidemiology and Biostatistics,
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationBenign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients
American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationCancer registry. Azin.Nahvijou, MD, PhD Candidate
Cancer registry Azin.Nahvijou, MD, PhD Candidate 1 History of Cancer registration: The first efforts to estimate the number of new and existing cases of cancer in a given population were made at the turn
More informationCancer survival in Chennai (Madras), India,
Cancer survival in Chennai (Madras), India, 199 1999 Swaminathan R, Rama R, Nalini S and Shanta V Abstract The Madras metropolitan tumour registry was established in 1981, and registration of incident
More informationFast Facts: Ovarian Cancer
Fast Facts Fast Facts: Ovarian Cancer Christina Fotopoulou MD PhD Consultant Gynaecological Oncologist Queen Charlotte s and Chelsea Hospital London, UK Thomas J Herzog MD Professor of Obstetrics and Gynecology
More informationHormone Therapy and Different Ovarian Cancers: A National Cohort Study
American Journal of Epidemiology Advance Access published April 19, 2012 American Journal of Epidemiology ª The Author 2012. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationImprovements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: http://www.tandfonline.com/loi/ionc20 Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance
More informationEUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA
EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF EUROCHIP-2 ACTION IN ESTONIA Impact of implementing a nationwide cervical cancer screening programme on population coverage by Pap-tests and on proportion
More informationCancer survival in Hong Kong SAR, China,
Chapter 5 Cancer survival in Hong Kong SAR, China, 1996 2001 Law SC and Mang OW Abstract The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods.
More informationNational Cervical Screening Programme. Annual Report 2014
National Cervical Screening Programme Annual Report 2014 Report prepared February 2017 Revised May 2017 Finalised June 2017 Report prepared by Megan Smith, Leanne Rumlee and Karen Canfell. Cancer Research
More informationOral contraception in Denmark
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Oral contraception in Denmark 1998 2010 NADIA M. WILSON 1, MAJA LAURSEN 2 & ØJVIND LIDEGAARD 1 1 Gynecological Clinic, Rigshospitalet University
More informationHuman epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts
Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with
More informationCurrent cancer incidence and trends in Yaounde, Cameroon
Short Communication OGH Reports Current cancer incidence and trends in Yaounde, Cameroon Enow Orock GE, 1 Ndom P, 2 Doh AS 2 1 Yaounde Cancer Registry, Cameroon 2 National Cancer Control Program, Yaounde,
More informationTrends in Lung Cancer Incidence by Histological Type in Osaka, Japan
Original Article Japanese Journal of Clinical Oncology Advance Access published August 9, 2008 Jpn J Clin Oncol 2008 doi:10.1093/jjco/hyn072 Trends in Lung Cancer Incidence by Histological Type in Osaka,
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationCancer survival in Bhopal, India,
Chapter 13 Cancer survival in Bhopal, India, 1991 1995 Dikshit R, Kanhere S and Surange S Abstract The Bhopal population-based cancer registry was established in 1986 under the national cancer registry
More informationENCR Call for Data 21 May 2010
E N C R EUROPEAN NETWORK OF CANCER REGISTRIES ENCR Secretariat International Agency for Research on Cancer 150 cours Albert Thomas 69372 Lyon Cedex 08 - France Tel.: +33 (0)472 73 84 66 Fax: +33 (0)472
More informationRaised CA-125 Levels in Patients with Suspected Cases of Ovarian Malignancy
Raised CA-125 Levels in Patients with Suspected Cases of Ovarian Malignancy DR. MARIA QIBTIA, MBBS NISHTAR HOSPITAL, MULTAN, PAKISTAN. DR. ZEENAT SHABBIR, MBBS NISHTAR HOSPITAL, MULTAN, PAKISTAN. DR. SAIMA
More informationRisk for anogenital cancer and other cancer among women hospitalized with gonorrhea
Acta Obstet Gynecol Scand 2001; 80: 757 761 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationOverview. All-cause mortality for males with colon cancer and Finnish population. Relative survival
An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert
More informationPeriod estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision
Journal of Clinical Epidemiology 59 (2006) 570 575 ORIGINAL ARTICLES Period estimates of cancer patient survival are more up-to-date than estimates even at comparable levels of precision Hermann Brenner
More informationTrends in Cure Fraction from Colorectal Cancer by Age and Tumour Stage Between 1975 and 2000, Using Population-based Data, Osaka, Japan
Epidemiology Note Jpn J Clin Oncol 2012;42(10)974 983 doi:10.1093/jjco/hys132 Advance Access Publication 5 September 2012 Trends in Cure Fraction from Colorectal Cancer by Age and Tumour Stage Between
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38705 holds various files of this Leiden University dissertation. Author: Gijn, Willem van Title: Rectal cancer : developments in multidisciplinary treatment,
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationTrends in the incidence of thyroid cancer, Israel,
Trends in the incidence of thyroid cancer, Israel, 1980-2012 Lital Keinan-Boker, MD, MPH, PhD, Barbara G. Silverman, MD, MPH Israel National Cancer Registry Israel Center for Disease Control Israel Ministry
More informationAnnual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
More informationThe improved cure fraction for esophageal cancer in Linzhou city
Liu et al. BMC Cancer (2018) 18:949 https://doi.org/10.1186/s12885-018-4867-7 RESEARCH ARTICLE Open Access The improved cure fraction for esophageal cancer in Linzhou city Shuzheng Liu 1, Lanwei Guo 1,
More informationAssociation between Age, Tumour Location and Survival of Patients in Morocco
Journal of Cancer and Tumor International 1(1):.., 2014 SCIENCEDOMAIN international www.sciencedomain.org Association between Age, Tumour Location and Survival of Patients in Morocco A. Sbayi 1, A. Arfaoui
More informationThe Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer
doi:10.21873/anticanres.11111 The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer MIKKEL ROSENDAHL, BERIT JUL MOSGAARD and CLAUS
More informationOvarian Cancer Prevalence:
Ovarian Cancer Prevalence: Basic Information 1. What is being measured? 2. Why is it being measured? The prevalence of ovarian cancer, ICD-10 C56 Prevalence is an indicator of the burden of cancer and
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationCancer in Pacific people in New Zealand: a descriptive study
Cancer in Pacific people in New Zealand: a descriptive study Abstract: Non-Mâori Pacific people constitute a significant and rapidly growing population in New Zealand. An accompanying change in lifestyle
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Cancer incidence and mortality among members of the Danish resistance movement deported to German concentration camps: 65-Year follow-up Maja Halgren Olsen 1, Henrik
More informationLung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 2009
Lung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 9 Sharma P Riaz Karen M Linklater Henrik Møller Margreet Lüchtenborg Contents 1. Introduction... 1 2. Methods...
More informationQuantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
British Journal of Cancer (2002) 87, 65 69 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
More informationReport on Cancer Statistics in Alberta. Childhood Cancer
Report on Cancer Statistics in Alberta Childhood Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationThe E-Cadherin Expression vs. Tumor Cell Proliferation Paradox in Endometrial Cancer
The E-Cadherin Expression vs. Tumor Cell Proliferation Paradox in Endometrial Cancer IRENE GONZÁLEZ-RODILLA 1, LAURA ALLER 2, JAVIER LLORCA 3, ANA-BELÉN MUÑOZ 2, VIRGINIA VERNA 2, JOSÉ ESTÉVEZ 2 and JOSÉ
More informationCancer survival in Harare, Zimbabwe,
Chapter 31 Cancer survival in Harare, Zimbabwe, 1993 1997 Chokunonga E, Borok MZ, Chirenje ZM, Nyabakau AM and Parkin DM Abstract The Zimbabwe national cancer registry was established in 1985 as a population-based
More informationTitle: Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study
Author's response to reviews Title: Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study Authors: Inger J Bakken (inger.bakken@sintef.no)
More informationEpidemiologic characteristics of cervical cancer in Korean women
Review Article J Gynecol Oncol Vol. 25, No. 1:70-74 pissn 2005-0380 eissn 2005-0399 Epidemiologic characteristics of cervical cancer in Korean women Hyun-Joo Seol, Kyung-Do Ki, Jong-Min Lee Department
More informationUp-to-date survival curves of children with cancer by period analysis
British Journal of Cancer (3) 88, 1693 1697 & 3 Cancer Research UK All rights reserved 7 9/3 $25. www.bjcancer.com Up-to-date survival curves of children with cancer by period analysis *,1 1 Department
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1-: Annual Report of the National Cancer Registry ABBREVIATIONS % CI % confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) CNS Central
More informationAbstract. Int J Gynecol Cancer 2006, 16,
Int J Gynecol Cancer 2006, 16, 1833 1838 Cervical cancer incidence and survival in Korea: 1993 2002 H.H. CHUNG*, M.J. JANGy, K.W. JUNGy, Y.J. WONy, H.R. SHINy, J.W. KIM* & H.-P. LEE* (ON BEHALF OF THE
More informationCANCER FACT SHEETS: LIVER CANCER
CANCER FACT SHEETS: LIVER CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance China WHO Western Pacific Region Less developed regions World WHO African Region United
More informationDownloaded from:
Li, R; Abela, L; Moore, J; Woods, LM; Nur, U; Rachet, B; Allemani, C; Coleman, MP (2014) Control of data quality for population-based cancer survival analysis. Cancer epidemiology, 38 (3). pp. 314-20.
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274
More informationThe EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies
Editorial Annals of Oncology 14 (Supplement 5): v9 v13, 2003 DOI: 10.1093/annonc/mdg750 The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies Cancer
More informationCancer survival in Khon Kaen, Thailand,
Cancer survival in Khon Kaen, Thailand, 1993 1997 Suwanrungruang K, Vatanasapt P, Kamsa-Ard S, Sriamporn S and Wiangnon S Abstract The Khon Kaen cancer registry was established in 1984 as a hospital-based
More informationAssessment of lead-time bias in estimates of relative survival for breast cancer
Assessment of lead-time bias in estimates of relative survival for breast cancer Therese M-L Andersson a,, Mark J Rutherford b, Keith Humphreys a a Department of Medical Epidemiology and Biostatistics,
More informationCervical Cancer and Pap Test Utilisation in Manitoba
Cervical Cancer and Pap Test Utilisation in Manitoba 1970-1999 Alain Demers Marion Harrison Grace Musto Kathleen Decker Robert Lotocki The Department of Epidemiology and Cancer Registry and the Manitoba
More informationDownloaded from:
Abdel-Rahman, M; Stockton, D; Rachet, B; Hakulinen, T; Coleman, MP (2009) What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? British journal of cancer, 101. S115-S124.
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
More informationZurich Open Repository and Archive. Variation in survival after diagnosis of breast cancer in Switzerland
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2005 Variation in survival after diagnosis of breast cancer in Switzerland Fisch,
More informationRESEARCH ARTICLE. Some Epidemiological Measures of Cancer in Kuwait: National Cancer Registry Data from
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.7.3113 Some Epidemiological Measures of Cancer in Kuwait: National Cancer Registry Data from 2000-2009 RESEARCH ARTICLE Some Epidemiological Measures of Cancer
More informationHEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017
HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths
More information